

- (4) Appendix B - currently pending claim set, incorporating the amendments made herein;
- (5) Appendix C - copy of form PCT/IB308 "Notice Informing the Applicant of the Communication of the International Application to the Designated Offices";
- (6) Appendix D - copy of the cover page of PCT/IB98/01665 filed October 9, 1998; and
- (7) Paper copy and computer readable form on CD (complete_seqlist09303518.txt; 2,240 KB; IBM-PC, MS-Windows) of new Sequence Listing.

AMENDMENT

In the Specification

Please replace the specification with the enclosed substituted specification in compliance with 37 CFR §§ 1.121(b)(3) and 1.125. The substitute specification is submitted for the Examiners convenience because the number of amendments to comply with the requirements of 37 CFR §§ 1.821-1.825, render the application difficult to examine. The substitute specification contains no new matter. A marked-up version of the filed specification accompanies this response.

After the ABSTRACT on page 622, line 6, please insert:

SEQUENCE LISTING

and insert pages 1-1074 of the Sequence Listing submitted herewith in the specification.

In the Claims:

Please cancel claims 1, 4-8 and 14-17 without prejudice or disclaimer of the subject matter contained therein.

Please amend claims 9, 10, 11, 12, 13 in the following manner.

9. (Amended) An isolated nucleic acid molecule comprising an open reading frame, wherein the open reading frame comprises:

(a) a nucleotide sequence selected from the group consisting of SEQ ID NO: 125, SEQ ID NO: 127, SEQ ID NO: 131, SEQ ID NO: 463, SEQ ID NO: 465, SEQ ID NO: 569, and SEQ ID NO: 571;

- (b) a fragment of (a) greater than 18 nucleotides in length;
- (c) a nucleotide sequence complementary to (a) or (b); and
- (d) a nucleotide sequence having 90% or greater sequence identity to (a), (b) or (c).

10. (Amended) An isolated nucleic acid molecule comprising an open reading frame, wherein the open reading frame comprises a fragment greater than 18 nucleotides in length of a nucleotide sequence selected from the group consisting of SEQ ID NO: 125, SEQ ID NO: 127, SEQ ID NO: 131, SEQ ID NO: 463, SEQ ID NO: 465, SEQ ID NO: 569, and SEQ ID NO: 571.

11. (Amended) An isolated nucleic acid molecule comprising a nucleotide sequence complementary to a nucleic acid molecule according to claim 9.

12. (Amended) An isolated nucleic acid molecule comprising an open reading frame, wherein the open reading frame comprises a nucleotide sequences having 90% or greater sequence identity to a nucleic acid molecule according claim 9.

13. (Amended) An isolated nucleic acid molecule which can hybridize to a nucleic acid molecule according to claim 9 under high stringency conditions.

Please add the following new claims.

18. (New) A recombinant vector comprising:

- (a) an isolated nucleic acid molecule according to claim 9; and
- (b) control elements that are operably linked to said nucleic acid molecule

whereby a coding sequence within said nucleic acid molecule can be transcribed and translated in a host cell, and at least one of said control elements is heterologous to said coding sequence.

19. (New) A host cell transformed with the recombinant vector of claim 18.

20. (New) A method of producing a recombinant polypeptide comprising:

- (a) providing a population of host cells according to claim 19; and
- (b) culturing said population of cells under conditions whereby the polypeptide encoded by the coding sequence present in said recombinant vector is expressed.

21. (New) An isolated nucleic acid molecule comprising an open reading frame, wherein the open reading frame comprises a nucleotide sequence selected from the group consisting of SEQ ID NO: 125, SEQ ID NO: 127, SEQ ID NO: 131, SEQ ID NO: 463, SEQ ID NO: 465, SEQ ID NO: 569, and SEQ ID NO: 571.

22. (New) A recombinant vector comprising:

- (a) an isolated nucleic acid molecule according to claim 21; and
- (b) control elements that are operably linked to said nucleic acid molecule whereby a coding sequence within said nucleic acid molecule can be transcribed and translated in a host cell, and at least one of said control elements is heterologous to said coding sequence.

23. (New) A host cell transformed with the recombinant vector of claim 21.

24. (New) A method of producing a recombinant polypeptide comprising:

- (a) providing a population of host cells according to claim 21; and
- (b) culturing said population of cells under conditions whereby the polypeptide encoded by the coding sequence present in said recombinant vector is expressed.

Attached hereto is a marked-up version of the changes to the claims by the current amendment captioned **“Version with markings to show changes made”** (Appendix A).